Nicholas Abbott, MD
Cardiovascular Disease · Tualatin, ORNPI 1124319330
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (45.0%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 69.1% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $21,229 and has fallen 98.7% since, to $272 in 2025. Among cardiovascular disease clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 159 payments — averaging $187.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$21K
- Boston Scientific$5K
- Abbott$3K
- Biosense Webster, Inc.$401
- Impulse Dynamics (USA) Inc.$255
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$195
- plus $430 from 12 others
What the payments were for
- Speaking & faculty fees$2,93810%
- Grants$13,40145%
- Travel & lodging$7,19324%
- Food & beverage$6,18121%
- Education$700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 42 | $20,567 |
| Boston Scientific | 59 | $4,844 |
| Abbott | 25 | $3,091 |
| Biosense Webster, Inc. | 5 | $401 |
| Impulse Dynamics (USA) Inc. | 3 | $255 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $195 |
| E.r. Squibb & Sons, L.L.C. | 5 | $136 |
| Cordis US CORP. | 2 | $51 |
| Pfizer | 2 | $40 |
| Heartflow, Inc. | 1 | $30 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $29 |
| Shockwave Medical, Inc | 1 | $26 |
| Lilly USA, LLC | 1 | $22 |
| Inari Medical, Inc. | 1 | $22 |
| Novartis | 1 | $20 |
| Bridgebio Pharma, Inc. | 1 | $19 |
| Bayer | 1 | $17 |
| Penumbra, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ensite Cardiac Mapping System$1,660
- Watchman$1,216
- GENERAL - THERAPIES$1,053
- GENERAL TACHY$901
- OPTIMIZER$474
- Carto 3$220
- AVEIR$143
- WATCHMAN Access System$123
- Amplia MRI$108
- JOT DX$104
- Carto 3 System$102
How this compares
$29,782 in reported general payments places this provider in the 90th percentile of 198 cardiovascular disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 295 | $340,264 |
| XareltoRivaroxaban | 57 | $61,872 |
| Dofetilide | 43 | $7,022 |
| Flecainide Acetate | 113 | $4,339 |
| Metoprolol Succinate | 286 | $4,073 |
| SotalolSotalol Hcl | 59 | $1,504 |
| Amiodarone Hcl | 47 | $818 |
| Digoxin | 17 | $633 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 24 | $621 |
| Carvedilol | 43 | $527 |
| Potassium Chloride | 23 | $472 |
| Enalapril Maleate | 12 | $441 |
| Metoprolol Tartrate | 66 | $420 |
| Losartan Potassium | 39 | $344 |
| Amlodipine Besylate | 34 | $279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $40 | $340,264295 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 198 cardiovascular disease providers in Oregon.
Other cardiovascular disease in Tualatin
- Kenneth LeclercTualatin$3K
- Firas ZahrPortland$810K
- Kathy GreweHood River$376K
- Scott ChadderdonPortland$282K
- Ahmad MasriPortland$227K
- Ashwat DhillonCorvallis$156K
- Stephen HeitnerPortland$105K
- Ian RiddockBend$81K
- Abhushan PoudyalPortland$54K
- Douglas DawleyPortland$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.